The pharmaceutical industry of the European Union is currently toiling at a veritably Herculean task. They jointly took up the fight against falsified pharmaceuticals in the legal supply chain. Forgers have discovered that falsified drugs are a lucrative business. However, the EU legislature has recognised this risk, and responded by passing the Falsified Medicines Directive in 2011. In 2016, it was put in more concrete terms with the delegated regulation, which stipulates the implementation of the directive for prescription drugs.
Investors purchase Imegen
Latest NewsThe investment groups Q-Growth Fund and Biolty purchased the majority of the Valencian biotechnology company Institute of Genomic Medicine (Imegen) for €10m.
Cell Medica bags €68,8 in Series C
Latest NewsBritish Cell Medica has closed a 60£ (€68,8m) Series C financing to advance its pipeline of virus-specific Natural Killer T (NKT) cells in oncology and viral infection.
Avantium raised €103m in oversubscribed IPO
Latest NewsAccording to main investor Sofinnova Partners, the Euronext IPO of Avantium, the front runner in renewable chemistry, was oversubscribed multiple times resulting in a market capitalisation of €277m.
NSCLC: Transgene launches cancer combo tests
Latest NewsTransgene has started Phase II efficacy testing of its therapeutic cancer vaccine TG4010 and Bristol-Myers Squibb’s checkpoint inhibitor Opdivo (nivolumab) in non-squamous non-small cell lung cancer (NSCLC).
Allogenic stem cell transplant safe in heart infarction patients
Latest NewsBelgian cell therapeutics specialist TiGenix NV announced positive top-line one-year results from its CAREMI stem cell study in acute myocardial infarction.
A clear path ahead for the bioeconomy
OpinionPharnext partners with Galapagos
Latest NewsNeurodegeneration specialist Pharnext SA and autoimmune disease expert Galapagos NV have inked an R&D contract in order to expand Pharnext’s pleotherapy approach to new indications.
Europe’s shield against falsified medicines
OpinionThe pharmaceutical industry of the European Union is currently toiling at a veritably Herculean task. They jointly took up the fight against falsified pharmaceuticals in the legal supply chain. Forgers have discovered that falsified drugs are a lucrative business. However, the EU legislature has recognised this risk, and responded by passing the Falsified Medicines Directive in 2011. In 2016, it was put in more concrete terms with the delegated regulation, which stipulates the implementation of the directive for prescription drugs.
BerGenBio plans IPO and partners with MSD
Latest NewsNorwegian BerGenBio ASA said it will go public at Oslo Børs and partnered with Merck & Co. for conducting Phase II combination studies of its oral Axl kinase blocker BGB324 with Merck’s PD-1 inhibitor pembrolizumab in lung cancer patients.
Next Big Thing in insurance: Digitalising Health
BackgroundTo date, insurance business models have always been based on damage control, but that paradigm is changing. Some insurers are now trying to hedge bets by motivating customers to get healthier and track that progress with the help of technology. Critics are concerned about data protection issues, and see this as a first step towards individualised premiums that will erode the principle of solidarity. What are the potential upsides and downsides for customers and societies?